COHBAR, INC. (OTCMKTS:CWBR) Files An 8-K Other Events

COHBAR, INC. (OTCMKTS:CWBR) Files An 8-K Other Events
Item 8.01 Other Information

Story continues below

On July 12, 2018, CohBar, Inc. issued a press release announcing its initiation of a Phase 1a/1b safety and biomarker study of CB4211, its lead candidate under development as a potential treatment for non-alcoholic steatohepatitis (NASH) and obesity. A copy of the press release is attached hereto as Exhibit 99.1.

Item 8.01 Financial Statements and Exhibits

(d) Exhibits

The following exhibit is furnished herewith and this list is intended to constitute the exhibit index:

99.1 CohBar, Inc. press release dated July 12, 2018.

CohBar, Inc. Exhibit
EX-99.1 2 f8k071218ex99-1_cohbarinc.htm COHBAR,…
To view the full exhibit click here

An ad to help with our costs